Skip to main content

Immunovant, Inc.

corporate_fare Company Profile

Immunovant, Inc.

IMVT·NASDAQ·Life Sciences·CIK 0001764013

Immunovant, Inc. is a clinical-stage immunology company focused on developing treatments for autoimmune diseases. The company's primary focus is on IMVT-1402 (imeroprubart), an inhibitor of the neonatal fragment crystallizable receptor (FcRn). FcRn plays a role in preventing the breakdown of immunoglobulin G (IgG) antibodies, and inhibiting FcRn can reduce levels of total IgG and pathogenic IgG antibodies. Immunovant believes FcRn inhibition has broad therapeutic potential for autoimmune diseases driven by pathogenic IgG, including those in endocrinology, neurology, rheumatology, and dermatology. Third-party estimates indicate that over four million patients in the United States and Europe could benefit from anti-FcRn treatments across more than 20 publicly announced indications. Two indications are already approved and have quickly achieved multi-billions of dollars in global annual sales. Consistent evidence from Phase 2 and 3 trials across eight indications with FcRn inhibitors shows that deeper IgG reductions correlate with significant improvements in clinical outcomes. Immunovant's own Phase 2 and 3 studies of its first-generation anti-FcRn antibody, batoclimab, in Graves' disease (GD), myasthenia gravis (MG), and chronic inflammatory demyelinating polyneuropathy (CIDP) demonstrated that IgG reductions of 70% or more led to better outcomes compared to reductions below 70%. In a Phase 1 clinical trial, healthy adults receiving IMVT-1402 showed deep, dose-dependent IgG reductions. The company anticipates achieving approximately 80% IgG reductions with continued weekly dosing of 600 mg of IMVT-1402, which would offer deeper IgG reductions than observed with other competitor anti-FcRn programs. In the Phase 1 trial, IMVT-1402 showed no or minimal reductions in albumin and no or minimal increases in LDL cholesterol levels across all evaluated doses, which are off-target effects seen with some other anti-FcRn antibodies, including batoclimab.

Immunovant, Inc. (NASDAQ:IMVT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for IMVT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for IMVT spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Immunovant Q2 Loss Narrows to $97.2M; $722.3M Cash Funds GD Launch
  • Immunovant's IMVT-1402 Hits ACR20 Endpoint in D2T RA; Sjogren's Program Shelved
  • Immunovant Posts Narrower-Than-Expected Q2 Loss of $97.2M
  • Immunovant's IMVT-1402 Hits Primary Endpoint in D2T RA With 92.5% ACR20 Response
  • Immunovant's IMVT-1402 Fails Primary Endpoint in Lupus Study, Development Halted

Financial Snapshot

Fiscal year ended March 31, 2026
Net Income
-$505.61M
Diluted EPS
-$2.77
Op. Cash Flow
-$407.31M
Free Cash Flow
-$407.32M
Cash & Equivalents
$902.11M
Debt / Equity
0.00×
Shares Outstanding
203.94M sh
Source: 10-K · filed 2026-05-20 · accession 0001764013-26-000064

Short Interest & Short Volume

15.26 days to cover

FINRA reported short interest of 18,550,107 shares in IMVT as of the October 30, 2026 settlement, a 1.5% increase from the prior period — about 15.3 days to cover at its recent average daily volume. On November 19, 2026, 61.8% of IMVT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)18,550,107 shares as of October 30, 2026
Change vs prior period▲ 1.5%
Days to cover15.26 at avg daily volume of 1,215,553
Daily short volume (FINRA facilities)61.8% of 276,600 shares on November 19, 2026
5-day average short volume66.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for IMVT, detected from its recent SEC filings · based on capital-structure filings through 2026-11-09.

ATM program1 shelf registration

New $150M ATM Program Registered · Dilution If Fully Used

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →
$31.51 -0.82% today
52-week range · as of 2026-11-09 $21.43 – $45.42
Market cap
$6.57B
Volume
704.9K (0.5× avg)
3-mo avg 1.4M
Live data · 2026-11-20 23:53 UTC · After hours

show_chartPrice Chart

Loading chart...

feed IMVT - Latest Insights

IMVT
Nov 09, 2026, 7:20 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.20
Real-time Price: $31.51 info
Change: -$3.69 (-10%) info
Market Cap: $6.575B info
IMVT
Nov 09, 2026, 7:09 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.85
Real-time Price: $31.51 info
Change: -$4.34 (-12%) info
Market Cap: $6.575B info
IMVT
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.10
Real-time Price: $31.51 info
Change: +$3.41 (+12%) info
Market Cap: $6.575B info
IMVT
Nov 09, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $28.10
Real-time Price: $31.51 info
Change: +$3.41 (+12%) info
Market Cap: $6.575B info
IMVT
Sep 23, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $36.20
Real-time Price: $31.51 info
Change: -$4.69 (-13%) info
Market Cap: $6.575B info
IMVT
Aug 07, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $39.74
Real-time Price: $31.51 info
Change: -$8.23 (-21%) info
Market Cap: $6.575B info
IMVT
Aug 06, 2026, 7:29 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $39.19
Real-time Price: $31.51 info
Change: -$7.68 (-20%) info
Market Cap: $6.575B info
IMVT
Aug 06, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $39.36
Real-time Price: $31.51 info
Change: -$7.85 (-20%) info
Market Cap: $6.575B info
IMVT
May 21, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $35.48
Real-time Price: $31.51 info
Change: -$3.97 (-11%) info
Market Cap: $6.575B info
IMVT
May 20, 2026, 7:28 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $32.54
Real-time Price: $31.51 info
Change: -$1.03 (-3%) info
Market Cap: $6.575B info
IMVT
May 20, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $32.66
Real-time Price: $31.51 info
Change: -$1.15 (-4%) info
Market Cap: $6.575B info
IMVT
May 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $31.03
Real-time Price: $31.51 info
Change: +$0.480 (+2%) info
Market Cap: $6.575B info
IMVT
Feb 06, 2026, 7:24 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.12
Real-time Price: $31.51 info
Change: +$7.39 (+31%) info
Market Cap: $6.575B info
IMVT
Feb 06, 2026, 7:16 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $24.12
Real-time Price: $31.51 info
Change: +$7.39 (+31%) info
Market Cap: $6.575B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets